Patents Assigned to SmithKline Beecham p.l.c.
  • Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity
    Publication number: 20020143029
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts and solvates: 1
    Type: Application
    Filed: May 23, 2002
    Publication date: October 3, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: John David Harling, Frank Peter Harrington, Mervyn Thompson
  • Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the TNF release
    Patent number: 6458779
    Abstract: Compounds of Formula (1) wherein: R is methyl substituted by one to three groups from alkyl, aryl, alkenyl, and alkynyl; n is ) or 1; R1 is arylmethyl or heterocyclylmethyl; R2 is alkyl, alkenyl, cycloalkyl or cycloalkenyl; and R3 is hydrogen, alkyl, alkenyl, alkynyl or aryl; are useful in the treatment of disorders mediated y s-CD23.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: October 1, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Andrew Faller, David Timothy MacPherson, Peter Henry Milner, Jayshree Mistry, John Gerald Ward
  • 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
    Publication number: 20020137940
    Abstract: A hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, characterized in that it: (i) comprises water in the range of from 0.4 to 2.5 %w/w; and (ii) provides an infra red spectrum containing peaks at 1749, 1703, 1645, 1623, 1365 and 736 cm−1; and/or (iii) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in Figure II and/or (iv) provides a Raman spectrum containing peaks at 3106, 3069, 3002, 2961, 1750, 1718, 1684, 1385, 1335, 1229, 1078, 917, 428 and 349 cm−1 and/or (iv) provides a solid-state nuclear magnetic resonance spectrum containing chemical shifts substantially as set out in Table I; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such a compound or composition in medicine.
    Type: Application
    Filed: February 26, 2002
    Publication date: September 26, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Michael John Sasse, Paul David James Blackler, David C. Lee
  • Substituted thiazolidined derivative, process for its preparation and its pharmaceutical use
    Publication number: 20020133016
    Abstract: A hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)thiazolidine-2,4-dione, maleic acid salt, characterized in that it: (i) comprises water in the range of from 0.3 to 0.6 molar equivalents; and (ii) provides an infra red spectrum containing peaks at 1757, 1331, 1290, 1211 and 767 cm−1; and/or (iii) provides a Raman spectrum containing peaks at 1758, 1610, 1394, 1316 and 1289 cm−1; and/or (iv) provides a solid state nuclear magnetic resonance spectrum containing chemical shifts substantially as set out in Table I herein; and/or (v) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in FIG. IV herein; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such a compound or composition in medicine.
    Type: Application
    Filed: February 8, 2002
    Publication date: September 19, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Ian Robert Lynch, Michael John Sasse, Bernadette Marie Choudary
  • Composition for treating dementia and Alzheimer's disease
    Patent number: 6451343
    Abstract: Controlled release dosage forms useful in the treatment and/or prophylaxis of dementia, including Alzheimer's disease, in mammals, and for enhancing amyloid precursor protein processing along a non-amyloidogenic pathway in patients suffering from, or at risk of developing, Alzeimer's disease.
    Type: Grant
    Filed: August 30, 2000
    Date of Patent: September 17, 2002
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Robert Glinecke, William Muldoon, Susan Marie Milosovich, Joseph Sauer, Laurence Rousseau
  • Medicament
    Publication number: 20020128300
    Abstract: The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the treatment of diabetic retinopathy.
    Type: Application
    Filed: August 14, 2001
    Publication date: September 12, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventor: James Hill
  • Formulation for the treatment and/or prophylaxis of dementia
    Publication number: 20020127271
    Abstract: A pharmaceutical composition for administration to the skin, which comprises [R-(Z)]-&agr;-(methoxyimino)-&agr;-(1-azabicyclo[2.2.2]oct-3-yl)acentonitrile or a pharmaceutically acceptable salt thereof together with a suitable pharmaceutically acceptable carrier, for the treatment or prophylaxis of dementia.
    Type: Application
    Filed: October 18, 2001
    Publication date: September 12, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventor: Dirk Marinus Johannes Van-Schie
  • Pharmaceutical composition containing bicyclic type compounds
    Publication number: 20020123630
    Abstract: A compound of formula (I) or pharmaceutically acceptable salt thereof: 1
    Type: Application
    Filed: December 17, 2001
    Publication date: September 5, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Wai Ngor Chan, John Morris Evans, Geoffrey Stemp, Neil Upton, Robert Nicholas Willette
  • Process for the preparation of thiazolidinedione derivatives
    Publication number: 20020120150
    Abstract: 1
    Type: Application
    Filed: February 26, 2002
    Publication date: August 29, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Robert Gordon Giles, Norman John Lewis, John Kirby Quick
  • Method for treating renal disease
    Publication number: 20020115699
    Abstract: A method for the treatment and/or prophylaxis of renal diseases including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease, and microalbuminuria which method comprises the administration of an effective, non-toxic amount of an insulin sensitiser to a human or non-human mammal in need thereof.
    Type: Application
    Filed: November 20, 2001
    Publication date: August 22, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventor: Robin Edwin Buckingham
  • Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant streptococcus pneumo-nia
    Publication number: 20020114842
    Abstract: Infections potentially caused by DRSP may be treated by a method which comprises administering a pharmaceutical formulation comprising either: for an adult or older child patient from 800 to 1100 mg amoxycillin and from 100 to 150 mg clavulanate in a weight ratio between 6:1 and 10:1 inclusive; or for a paediatric patient from 30 to 40 mg/kg body weight of amoxycillin and from 3 to 8 mg/kg body weight of clavulanate in a weight ratio between 6:1 and 10:1 inclusive; in combination with a pharmaceutically acceptable carrier or excipient, three times a day(tid).
    Type: Application
    Filed: October 19, 2001
    Publication date: August 22, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventor: Richard Peregrine Bax
  • Macaca cynomolgus IL 18
    Patent number: 6432678
    Abstract: Macaca cynomolgus IL18 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds which either agonize or antagonize Macaca cynomolgus IL18. Such compounds are expected to be useful in treatment of human diseases, including, but not limited to: cancer and auto-immune diseases.
    Type: Grant
    Filed: June 20, 2000
    Date of Patent: August 13, 2002
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Alexander H. Taylor, Han N. Trinh
  • Pharmaceutical composition prepared by addition of a flavor vehicle to a medicament
    Patent number: 6428808
    Abstract: The invention relates to a method for preparing a flavored liquid medicament, particularly a pediatric preparation in solid form.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: August 6, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Philip Christopher Buxton, Janice Duncan, Wendy Johnson, Geoffrey David Tovey
  • Calcium mupirocin sprayable formulation
    Patent number: 6426363
    Abstract: Mupirocin or a salt or ester thereof may be used to treat recurrent sinusitis and recurrent otitis, in particular with novel spray or cream formulations adapted for administration to the nasopharynx.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: July 30, 2002
    Assignees: SmithKline Beecham P.L.C., SmithKline Beecham Corporaton
    Inventors: Timothy John Henkel, Anthony Guy Hatton, Teresita Regina Geradine Tallon, Hugh Scott, Jane Elizabeth Hilton
  • Neurotransmitter transporter SC6
    Patent number: 6426405
    Abstract: The SC6 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SC6 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: July 30, 2002
    Assignee: SmithKline Beecham P.L.C.
    Inventors: Anthony M Brown, Conrad Gerald Chapman, Israel Simon Gloger, Joanne Rachel Evans, William Cairns, Hugh Jonathan Herdon
  • Polynucleotides encoding a human potassium channel
    Patent number: 6426197
    Abstract: h-TRAAK polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing h-TRAAK polypeptides and polynucleotides in diagnostic assays.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: July 30, 2002
    Assignee: SmithKline Beecham, P.L.C.
    Inventors: David Malcolm Duckworth, Conrad Gerald Chapman
  • Use of glucose uptake enhancer for reducing apoptosis
    Publication number: 20020099082
    Abstract: A method for reducing or preventing apoptosis of differentiated cells selected from the list consisting of cardiac myocytes, pancreatic beta cells, endothelial cells and neuronal cells in the human or non-human mammal, which method comprises administration, including acute administration, of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
    Type: Application
    Filed: February 7, 2002
    Publication date: July 25, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Antoine Michel Alain Bril, Robin Edwin Buckingham, Nassirah Khandoudi
  • Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
    Publication number: 20020099081
    Abstract: The present invention provides a novel hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid.
    Type: Application
    Filed: February 7, 2002
    Publication date: July 25, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Michael John Sasse, Paul David James Blackler, David C. Lee
  • Sulphonamide derivatives, process for their preparation, and their use as medicaments
    Patent number: 6423717
    Abstract: Novel sulphonamide derivatives having CNS activity, processes for their preparation and their use as medicaments are disclosed.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: July 23, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Steven Mark Bromidge, Francis David King, Paul Adrian Wyman
  • Solid composition for reducing tooth erosion
    Publication number: 20020090347
    Abstract: Solid or semi-solid acidic oral composition comprising having reduced tooth erosion characteristics are prepared by adding a calcium compound to an acid composition so that the mol ratio of calcium to acid ranges from 0.3 to 0.8, and the effective pH of the composition, if necessary after adjustment with an alkali, is from 3.5 to 4.5.
    Type: Application
    Filed: January 17, 2002
    Publication date: July 11, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventor: David Myatt Parker